Class III Antiarrhythmic Drugs: Amiodarone, Ibutilide, and Sotalol

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 932-941

  Smith, Timothy W ^a,b   Cain, Michael E ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904142486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50104-4     Document Type: Chapter

References (58)

1. Kaumann AJ, Olson CB Temporal relation between long-lasting aftercontractions and action potential in cat papillary muscles. Science 1968, 161:293-295.
2. Singh BN, Vaughan-Williams EM A third class of anti-arrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological action on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970, 39:675-687.
3. Ackerman MJ The long QT syndrome: Ion channel diseases of the heart. Mayo Clin Proc 1998, 73:250-269.
4. Kowey PR, Marinchak RA, Rials SJ, Bharucha D Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am J Cardiol 1997, 80:16G-23G.
5. Castro A, Bianconi L, Santini M New antiarrhythmic drugs for the treatment of atrial fibrillation. Pacing Clin Electrophysiol 2002, 25:249-259.
6. Kodama I, Kamiya K, Toyama J Cellular electropharmacology of amiodarone. Cardiovasc Res 1997, 35:13-29.
7. + current. Circulation 2001, 103:1317-1324.
8. Harjai KJ, Licata AA Effects of amiodarone on thyroid function. Ann Intern Med 1997, 126:68-73.
9. + channel activities of cultured rat cardiomyocytes. J Mol Cell Cardiol 1997, 29:617-627.
10. Podrid PJ Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995, 122:689-700.
11. Venkatesh N, Padbury JF, Singh BN Effects of amiodarone and desethyamiodarone on rabbit myocardial beta-adrenoceptors and serum thyroid hormones-Absence of relationship to serum and myocardial drug concentrations. J Cardiovasc Pharmacol 1986, 8:989-997.
12. The CASCADE Investigators Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993, 72:280-287.
13. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997, 349:667-674.
14. Cairns JA, Connolly Stuart J, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997, 349:675-682.
15. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low dose amiodarone in severe congestive heart failure. Lancet 1994, 344:493-498.
16. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995, 333:77-82.
17. Sim I, McDonald KM, Lavori PW, et al. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997, 96:2823-2829.
18. Amiodarone Trials Meta-Analysis Investigators Effect of prophylactic amiodarone on mortality after acute myocardial infarction and congestive heart failure: Meta-analysis of individual data from 6500 patients and randomised trials. Lancet 1997, 350:1417-1424.
19. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med 2000, 160:1741-1748.
20. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576-1583.
21. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996, 335:1933-1940.
22. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999, 341:1882-1890.
23. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995, 92:3255-3263.
24. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2001, 346:884-890.
25. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000, 342:913-920.
26. Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the atrial fibrillation suppression trial (AFIST): A randomized placebo-controlled trial. Lancet 2001, 357:830-836.
27. Singh BN Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 1997, 78:41-53.
28. Vorperian VR, Havighurst TC, Miller S, January CT Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997, 30:791-798.
29. Drouin E, Lande G, Charpentier F Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 1998, 32:1063-1067.
30. Kharabsheh S, Abendroth CS, Kozak M Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002, 89:896-898.
31. Siniakowicz RM Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan. J Cardiovasc Electrophysiol 2000, 12:431-436.
32. Jafari-Fesharaki M, Scheinman MM Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998, 21:108-120.
33. Goichot B, Grunenberger F, Schlienger J-L Amiodarone-induced hyperthyroidism. Arch Intern Med 2001, 161:295.
34. Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: Occurrence and epidemiology. Thyroid 1998, 8:83-100.
35. Harjai KJ, Licata AA Amiodarone induced hyperthyroidism: A case series and brief review of the literature. Pacing Clin Electrophysiol 1996, 19:1548-1554.
36. High WA, Weiss SD Pigmentation related to amiodarone. N Engl J Med 2001, 354:1464.
37. Pelosi F, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000, 11:736-740.
38. + current through a nifedipine inhibited inward channel. J Pharmacol Exp Ther 1998, 286:9-22.
39. + current in rabbit sinoatrial and atrioventricular node cells. Eur J Pharmacol 2000, 404:281-288.
40. Murray KT Ibutilide. Circulation 1998, 97:493-497.
41. Ellenbogan KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996, 28:130-136.
42. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996, 94:1613-1621.
43. Stambler BS, Wood MA, Ellenbogan KA Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996, 77:960-966.
44. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999, 340:1849-1854.
45. Murdock DK, Schumock GT, Kaliebe J, et al. Clinical and cost comparison of ibutilide and direct current cardioversion for atrial fibrillation and flutter. Am J Cardiol 2000, 85:503-506.
46. Anderson JL, Prystowsky EN Sotolol: An important new antiarrhythmic drug. Am Heart J 1999, 137:388-409.
47. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patient with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival With Oral d-Sotalol. Lancet 1996, 348:7-12.
48. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999, 340:1855-1862.
49. Dorian P, Newman D, Sheahan R, et al. d-Sotalol decreases defibrillation energy requirements in humans: A novel indication for drug therapy. J Cardiovasc Electrophysiol 1996, 7:952-961.
50. Gallik DM, Kim SG, Ferrick KJ, et al. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J 1997, 134:155-160.
51. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or flutter. Am J Cardiol 1999, 84:270-277.
52. Tsikouris JP, Cox CD A review of class III antiarrhythmic agents for atrial fibrillation: Maintenance of normal sinus rhythm. Pharmacotherapy 2001, 21:1514-1529.
53. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind placebo-controlled study. Am Heart J 1995, 129:739-748.
54. MacNeil DJ The side effect profile of class III antiarrhythmic drugs: Focus on d,l-sotalol. Am J Cardiol 1997, 80:90G-98G.
55. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998, 32:169-176.
56. Zimetbaum PJ, Schreckengost V, Cohen DJ, et al. Evaluation of out-patient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. Am J Cardiol 1999, 83:450-453.
57. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
58. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002, 143:984-990.